account_id none on file
legal_name Evaxion A/S
ticker EVAX
cik 1828253
domain evaxion.ai
linkedin_company_url https://www.linkedin.com/company/evaxion-biotech/
entry_point_account_id none on file
name Evaxion Biotech A/S
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 10 executives 0 family 0
why_nownone on file
callsnone on file
filings
Directors will be reimbursed for travel, food, lodging and other expenses directly related to their service as directors.
filing / Mar 5, 2026 / receipt
Karmark resigned as the Chief Financial Officer of the Company effective March 1, 2024. Number of warrants exclude non-employee warrants as referred to in Note 6.
filing / Mar 5, 2026 / receipt
Schmidt joined us on November 01, 2024, as the Chief Financial Officer. (3) Dr. Rønø was appointed interim Chief Executive Officer from July 1, 2025, to November 24, 2025, in addition to her role as Chief Scientific Officer.
filing / Mar 5, 2026 / receipt
In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures.
filing / Mar 5, 2026 / receipt
As previously mentioned, a primary trend in the United States health care industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products and services, implementing reductions in Medicare and other health care funding and applying new payment methodologies.
filing / Mar 5, 2026 / receipt
The office space commenced in February 2021 and the laboratory space commenced in August 2021. The initial monthly payment was $28,800 and the lease is subject to two to four percent increases in annual lease payment throughout the term.
filing / Mar 5, 2026 / receipt
Decrease in General and Administrative (G&A) expenses is primarily driven by lower capital market costs
ir_statement / Sep 15, 2026 / receipt
Decrease in General and Administrative (G&A) expenses is primarily driven by lower capital market costs
ir_statement / Sep 15, 2026 / receipt
EVX-04 is, we have done target discovery, we have selected the leads, and now we are conducting IND enabling activities so that includes the GMP manufacturing and then of course we need to check that
company_statement / Aug 20, 2026 / receipt, needs a key
we are of course always interested and are engaging with companies. So yeah, but it's not necessarily dependent on us entering into a partnership. | Target BD leaders with platforms that accelerate IN
company_statement / Aug 20, 2026 / receipt, needs a key
executivesnone on file
familynone on file
upcoming
changesnone on file
mcp_package_hint
slug evaxion-biotech-a-s
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$